Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 17/20 | 0.82 |
| ▸ | CCKAR | P32238 | 3/20 | 0.73 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29408672 | 0.99 | CCKBR (0.83) | CCKBRCCKAR | |
| SCHEMBL31236196 | 0.99 | CCKBR (0.83) | CCKBRCCKAR | |
| SCHEMBL29709573 | 0.99 | CCKBR (0.83) | CCKBRCCKAR | |
| SCHEMBL30816027 | 0.99 | CCKBR (0.83) | CCKBRCCKAR | |
| SCHEMBL31015828 | 0.98 | CCKBR (0.82) | CCKBRCCKAR | |
| SCHEMBL31378333 | 0.98 | CCKBR (0.82) | CCKBRCCKAR | |
| SCHEMBL31015850 | 0.97 | CCKBR (0.83) | CCKBRCCKAROPRD1 | |
| SCHEMBL30305897 | 0.97 | CCKBR (0.83) | CCKBRCCKAROPRD1 | |
| SCHEMBL29497501 | 0.96 | CCKBR (0.75) | CCKBRCCKAROPRD1 | |
| SCHEMBL31015859 | 0.95 | CCKBR (0.77) | CCKBRCCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3684395-B1 | MINIGASTRIN DERIVATES, IN PARTICULAR FOR USE IN CCK2 RECEPTOR POSITIVE TUMOUR DIAGNOSIS AND/OR TREATMENT | SCHERRER INST PAUL (CH) | 2024-06-19 | — | — | EP | claimed |
| EP-4329827-A1 | TARGETING SYSTEM FOR CANCER COMPRISING A RADIOISOTOPE | Alphathera AG (CH) | 2024-03-06 | — | — | EP | claimed |
| WO-2022231424-A1 | TARGETING SYSTEM FOR CANCER COMPRISING A RADIOISOTOPE | ALPHATHERA AG (CH) | 2022-11-03 | — | — | WO | claimed |
| US-12605447-B2 | Stable formulations for radionuclide complexes | ITM SOLUCIN GMBH (DE) | 2026-04-21 | — | — | US | disclosed |
| US-20250170243-A1 | STABLE FORMULATIONS FOR RADIONUCLIDE COMPLEXES | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2025-05-29 | — | — | US | disclosed |
| US-20240374732-A1 | STABLE FORMULATIONS FOR RADIONUCLIDE COMPLEXES | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2024-11-14 | — | — | US | disclosed |
| US-20230414796-A1 | COMBINATION OF PARA-AMINOHIPPURIC ACID (PAH) AND RADIOLABELED COMPLEXES FOR TREATING CANCER | ITM Isotope Technologies Munich SE (DE) | 2023-12-28 | — | — | US | disclosed |
| EP-4065176-B1 | COMBINATION OF PARA-AMINOHIPPURIC ACID (PAH) AND RADIOLABELED COMPLEXES FOR TREATING CANCER | ITM ISOTOPE TECH MUNICH SE (DE) | 2023-10-11 | — | — | EP | disclosed |
| EP-4218749-A1 | PARA-AMINOHIPPURIC ACID (PAH) AS A RENAL PROTECTIVE SUBSTANCE | ITM Isotope Technologies Munich SE (DE) | 2023-08-02 | — | — | EP | disclosed |
| EP-3965751-B1 | PARA-AMINOHIPPURIC ACID (PAH) AS A RENAL PROTECTIVE SUBSTANCE | ITM ISOTOPE TECH MUNICH SE (DE) | 2022-12-28 | — | — | EP | disclosed |
| US-20220396621-A1 | TARGETING AGENT ANTIBODY CONJUGATES AND USES THEREOF | SCRIPPS RESEARCH INST (US) | 2022-12-15 | — | — | US | disclosed |
| US-20220304964-A1 | PARA-AMINOHIPPURIC ACID (PAH) AS A RENAL PROTECTIVE SUBSTANCE | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2022-09-29 | — | — | US | disclosed |
| US-11377496-B2 | Targeting agent antibody conjugates and uses thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-07-05 | — | — | US | disclosed |
| CN-114126654-A | Para-aminohippuric acid (PAH) as a kidney protective substance | 同位素技术慕尼黑有限公司 | 2022-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605447-B2 | Stable formulations for radionuclide complexes | EPOR, CD47, PRCP | CCKBR 107/4885CCKAR 88/4885OPRD1 797/4885 |
| US-20250170243-A1 | STABLE FORMULATIONS FOR RADIONUCLIDE COMPLEXES | SLC40A1, SLC7A11, GYPA | CCKBR 1119/4885CCKAR 1147/4885OPRD1 3845/4885 |
| US-20220304964-A1 | PARA-AMINOHIPPURIC ACID (PAH) AS A RENAL PROTECTIVE SUBSTANCE | PAH, SLCO1B1, SLCO2B1 | CCKBR 1100/4885CCKAR 855/4885OPRD1 3805/4885 |
| US-20220396621-A1 | TARGETING AGENT ANTIBODY CONJUGATES AND USES THEREOF | CD22, FCGR2A, CD47 | CCKBR 1685/4885CCKAR 1464/4885OPRD1 1926/4885 |
| US-20240374732-A1 | STABLE FORMULATIONS FOR RADIONUCLIDE COMPLEXES | SLC40A1, SLC7A11, GYPA | CCKBR 1085/4885CCKAR 1163/4885OPRD1 3821/4885 |
| US-20230414796-A1 | COMBINATION OF PARA-AMINOHIPPURIC ACID (PAH) AND RADIOLABELED COMPLEXES FOR TREATING CANCER | PAH, VHL, SLC10A6 | CCKBR 389/4885CCKAR 404/4885OPRD1 4054/4885 |
| US-11377496-B2 | Targeting agent antibody conjugates and uses thereof | FCGR2A, CD22, FCGR3B | CCKBR 1154/4885CCKAR 1046/4885OPRD1 2485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.